CareRx Welcomes Stability in Long-Term Care Pharmacy Funding in Ontario
Toronto, Ontario--(Newsfile Corp. - April 16, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, welcomes the Ontario Ministry of Health's recent Executive Officer Notice confirming the current annual pharmacy long-term care capitation rate of $1,500 per licensed bed will be maintained and that the Ministry will not implement previously scheduled red
2026-04-16 4:30 PM EDT | CareRx Corporation
medmix' Shareholders Approve All Proposals at Annual General Meeting 2026
medmix AG Neuhofstrasse 20 CH-6430 Baar communications@medmix.com www.medmix.swiss DOWNLOAD
Technology, Construction / Building, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-04-16 8:37 AM EDT | medmix AG
Envoy Medical Appoints Chas McKhann to Board of Directors
White Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced the appointment of Chas McKhann, a seasoned medical technology executive with documented success, to its Board of Directors. Mr. McKhann is a well-known and respected med tech leader with extensive experience cre
Biotechnology, Healthcare and Hospitals
2026-04-16 8:00 AM EDT | Envoy Medical, Inc.
Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO
Calgary, Alberta--(Newsfile Corp. - April 16, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces the revocation, effective April 15, 2026, of a management cease trade order ("MCTO") issued by the Alberta Securities Commission (the "ASC") on April 1, 2026 at the request of the Company. The Company filed its audited financial statements, management's discussion & analysis, certifications of annual filings, and annual information form for the year
Technology, Biotechnology, Healthcare and Hospitals
2026-04-16 7:15 AM EDT | Resverlogix Corp.
Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercialization of GRAFAPEX™ (treosulfan) for Injection in the United States and on certain recent capital allocation and capital structure developments and announced company management's participation in two upcoming investor conferences. All dollar amounts in this news release are in US dollars unle
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-15 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Patient Safety Must Remain the Foundation of Scope of Practice Decisions in Canada
Ottawa, Ontario--(Newsfile Corp. - April 15, 2026) - As scope of practice expansion is actively being considered across Canada, the Canadian Ophthalmological Society (COS) is emphasizing that patient safety must remain the central and non-negotiable principle guiding any changes to healthcare delivery. While COS supports innovation and system modernization, it is deeply concerned that several proposed changes would expand independent clinical authority to non-physician providers without
Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-15 12:05 PM EDT | Canadian Ophthalmological Society (COS)
La sécurité des patients doit demeurer le fondement des décisions relatives au champ de pratique au Canada
Ottawa, Ontario--(Newsfile Corp. - 15 avril 2026) - Alors que l'élargissement des champs de pratique est activement envisagé à travers le Canada, la Société canadienne d'ophtalmologie (SCO) rappelle que la sécurité des patients doit demeurer le principe central et non négociable guidant toute évolution de la prestation des soins de santé. Bien que la SCO appuie l'innovation et la modernisation du système, elle demeure profondém
Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-15 12:05 PM EDT | Canadian Ophthalmological Society (COS)
Scryb Approves Proposed Name Change and Grant of Stock Options
Toronto, Ontario--(Newsfile Corp. - April 15, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company"), is pleased to announce that it intends to complete its corporate name change to NorthPalm Capital Corp., marking the next phase in the Company's evolution and reflecting a renewed strategic focus on shareholder value creation and disciplined growth. Under the new NorthPalm Capital, the Company plans to focus on timing, execution, and high-growth opportunities, suppo
Biotechnology, Healthcare and Hospitals, Health
2026-04-15 11:34 AM EDT | Scryb Inc.
Adia Nutrition, Inc. Announces Corporate Name Change to Adia Med, Inc. to Better Align with Its Regenerative Medicine and Biologics Business Model
Winter Park, Florida--(Newsfile Corp. - April 15, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a publicly traded company focused on regenerative medicine, stem cell therapies, and biologic products, today announced that it is in the process of changing its corporate name to Adia Med, Inc. The name change reflects the company's evolving business model, which has shifted significantly toward advanced medical treatments and biologics. Adia now operates through key divisions inclu
Healthcare and Hospitals, Health
2026-04-15 8:30 AM EDT | Adia Nutrition Inc.
CareRx Corporation Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 15, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, will be participating in the 2026 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 21-22, 2026, at the Metro Toronto Convention Centre. Puneet Khanna, President & Chief Executive Officer and Suzanne Brand, Ch
2026-04-15 7:30 AM EDT | CareRx Corporation
FendX Engages Galenvs for Pilot Scale-Up Manufacturing of Its Liquid Surface Coating
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection solutions to reduce the spread of harmful pathogens, announces the signing of a statement of work ("SOW") dated April 14, 2026 with Galenvs Sciences Inc. ("Galenvs"), a Canadian contract manufacturing and service organization, to initiate pilot-scale manu
Technology, Healthcare and Hospitals, Health
2026-04-15 7:00 AM EDT | FendX Technologies Inc.
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant
Ad hoc announcement pursuant to Art. 53 LR Long-term safety profile comparable to vehicle supports suitability for chronic use in a lifelong condition. Patients who remained on continuous Clascoterone treatment continued to gain hair through Month 12. In contrast, patients who switched to the placebo from Month 7 onwards experienced a reduction in treatment gains, demonstrating the importance of ongoing therapy. NDA a
Healthcare and Hospitals, Health
2026-04-15 1:07 AM EDT | Cosmo Pharmaceuticals N.V.
Veritas Association Management Welcomes Society for the Advancement of Patient Blood Management
Chicago, Illinois--(Newsfile Corp. - April 14, 2026) - Veritas Association Management (Veritas) announces that it has been selected to provide full-service association management services to the Society for the Advancement of Patient Blood Management (SABM), a nonprofit organization dedicated to advancing patient blood management practices to improve clinical outcomes and patient safety worldwide. SABM is a multidisci
2026-04-14 4:40 PM EDT | Veritas Association Management
Jones Healthcare Group's Near-Term Emissions Reduction Targets Validated by the Science Based Targets Initiative
London, Ontario--(Newsfile Corp. - April 14, 2026) - Jones Healthcare Group's near-term greenhouse gas emissions reduction targets have been approved by the Science Based Targets initiative (SBTi), marking a significant step in the company's commitment to reducing emissions across its operations and broader value chain. As part of its validated targets, Jones commits to reduce absolute scope 1 and scope 2 greenhouse gas emissions 43.26% by 2030 from a 2023 base year. The company also c
Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-14 10:00 AM EDT | Jones Healthcare Group
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the Company has been selected as one of the top four innovators to present its liquid biopsy platform at the annual Canadian Thoracic Society (CTS) Research Forum. The presentation will take place in front of a panel of expe
Technology, Biotechnology, Healthcare and Hospitals
2026-04-14 8:30 AM EDT | BioMark Diagnostics, Inc.
Fotonara and PhantomOmics Announce Revolutionary Partnership and "Good for All Humans" Initiative to Transform Affordable Housing into Sovereign Health Guardians
Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Fotonara Inc., a pioneer in advanced manufacturing and sovereign smart building infrastructure, and PhantomOmics Inc., a visionary in proactive health technology, today announced a landmark global commercialization partnership. Together, the two Calgary-based tech innovators are launching the "Good for All Humans" initiative—a sweeping joint mission to make high-fidelity, preventative health monitoring a standard, low-cost uti
Technology, Healthcare and Hospitals, Sensor, Health
2026-04-13 8:15 AM EDT | PhantomOmics Inc.
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses has demonstrated a complete response of all animals treated with X-Ray-activated Rutherrin® in a preclinical animal model of M
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-04-13 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using it
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
Voting Results of Cosmo's 2026 AGM
Dublin, Ireland--(Newsfile Corp. - April 10, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting (AGM). A total of 10,354,065 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 59.02% of the total outstanding ordinary shares in the share capital of Cosmo as of the record
Healthcare and Hospitals, Health
2026-04-10 9:16 AM EDT | Cosmo Pharmaceuticals N.V.
Theralase(R) Closes $CAN 2.66 Million Financing
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering ("Offering
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-04-10 7:00 AM EDT | Theralase Technologies Inc.